151 related articles for article (PubMed ID: 35367599)
21. Disulfiram, an alcohol dependence therapy, can inhibit the in vitro growth of Francisella tularensis.
Hamblin KA; Flick-Smith H; Barnes KB; Pereira-Leal JB; Surkont J; Hampson R; Atkins HS; Harding SV
Int J Antimicrob Agents; 2019 Jul; 54(1):85-88. PubMed ID: 31029736
[TBL] [Abstract][Full Text] [Related]
22. Bixa orellana L. (Achiote, Annatto) as an antimicrobial agent: A scoping review of its efficiency and technological prospecting.
Coelho Dos Santos D; Silva Barboza AD; Ribeiro JS; Rodrigues Junior SA; Campos ÂD; Lund RG
J Ethnopharmacol; 2022 Apr; 287():114961. PubMed ID: 34968663
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial peptides: new candidates in the fight against bacterial infections.
Toke O
Biopolymers; 2005; 80(6):717-35. PubMed ID: 15880793
[TBL] [Abstract][Full Text] [Related]
24. Organic and inorganic antibacterial approaches in combating bacterial infection for biomedical application.
Saidin S; Jumat MA; Mohd Amin NAA; Saleh Al-Hammadi AS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111382. PubMed ID: 33254989
[TBL] [Abstract][Full Text] [Related]
25. Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
Ketola K; Kallioniemi O; Iljin K
PLoS One; 2012; 7(12):e51470. PubMed ID: 23251544
[TBL] [Abstract][Full Text] [Related]
26. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
27. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).
Yotsu RR; Richardson M; Ishii N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012118. PubMed ID: 30136733
[TBL] [Abstract][Full Text] [Related]
28. Hybrid combinations containing natural products and antimicrobial drugs that interfere with bacterial and fungal biofilms.
Zacchino SA; Butassi E; Cordisco E; Svetaz LA
Phytomedicine; 2017 Dec; 37():14-26. PubMed ID: 29174600
[TBL] [Abstract][Full Text] [Related]
29. Bacteriocin-Based Synergetic Consortia: a Promising Strategy to Enhance Antimicrobial Activity and Broaden the Spectrum of Inhibition.
Soltani S; Biron E; Ben Said L; Subirade M; Fliss I
Microbiol Spectr; 2022 Feb; 10(1):e0040621. PubMed ID: 35170996
[TBL] [Abstract][Full Text] [Related]
30. Reasons for antimicrobial treatment failures and predictive value of in-vitro susceptibility testing in veterinary practice: An overview.
Richter A; Feßler AT; Böttner A; Köper LM; Wallmann J; Schwarz S
Vet Microbiol; 2020 Jun; 245():108694. PubMed ID: 32456814
[TBL] [Abstract][Full Text] [Related]
31. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis.
Wang J; Zhang H; Yan J; Zhang T
J Matern Fetal Neonatal Med; 2022 Mar; 35(5):861-870. PubMed ID: 32102584
[TBL] [Abstract][Full Text] [Related]
32. Gallesia integrifolia (Spreng.) Harms: In vitro and in vivo antibacterial activities and mode of action.
Arunachalam K; Ascêncio SD; Soares IM; Souza Aguiar RW; da Silva LI; de Oliveira RG; Balogun SO; de Oliveira Martins DT
J Ethnopharmacol; 2016 May; 184():128-37. PubMed ID: 26945980
[TBL] [Abstract][Full Text] [Related]
33. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.
Skrott Z; Mistrik M; Andersen KK; Friis S; Majera D; Gursky J; Ozdian T; Bartkova J; Turi Z; Moudry P; Kraus M; Michalova M; Vaclavkova J; Dzubak P; Vrobel I; Pouckova P; Sedlacek J; Miklovicova A; Kutt A; Li J; Mattova J; Driessen C; Dou QP; Olsen J; Hajduch M; Cvek B; Deshaies RJ; Bartek J
Nature; 2017 Dec; 552(7684):194-199. PubMed ID: 29211715
[TBL] [Abstract][Full Text] [Related]
34. Design and Discovery of New Antibacterial Agents: Advances, Perspectives, Challenges.
Jampilek J
Curr Med Chem; 2018; 25(38):4972-5006. PubMed ID: 28925868
[TBL] [Abstract][Full Text] [Related]
35. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
Garrison MW; Neumiller JJ; Setter SM
Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
[TBL] [Abstract][Full Text] [Related]
36. Systematic review of the effects of antimicrobial cycling on bacterial resistance rates within hospital settings.
Chatzopoulou M; Reynolds L
Br J Clin Pharmacol; 2022 Mar; 88(3):897-910. PubMed ID: 34409640
[TBL] [Abstract][Full Text] [Related]
37. Disulfiram: Mechanisms, Applications, and Challenges.
Lanz J; Biniaz-Harris N; Kuvaldina M; Jain S; Lewis K; Fallon BA
Antibiotics (Basel); 2023 Mar; 12(3):. PubMed ID: 36978391
[No Abstract] [Full Text] [Related]
38. Models of In-Vivo Bacterial Infections for the Development of Antimicrobial Peptide-based Drugs.
Brunetti J; Falciani C; Bracci L; Pini A
Curr Top Med Chem; 2017; 17(5):613-619. PubMed ID: 27411321
[TBL] [Abstract][Full Text] [Related]
39. [Antibiotheraphy in the 21st century, antibacterials for the second decade. Posibilities or realities in the future?].
García-Sánchez JE; García-Merino E; Martín-del-Rey A; García-Sánchez E
Rev Esp Quimioter; 2012 Jun; 25(2):100-21. PubMed ID: 22707099
[TBL] [Abstract][Full Text] [Related]
40. Intestinal microbiota regulates anti-tumor effect of disulfiram combined with Cu
Hu H; Cui L; Lu J; Wei K; Wei J; Li S; Zou C; Chen T
Cancer Med; 2020 Sep; 9(18):6791-6801. PubMed ID: 32750218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
